PNC FINANCIAL SERVICES GROUP, INC. - PROGENICS PHARMACEUTICALS IN ownership

PROGENICS PHARMACEUTICALS IN's ticker is PGNX and the CUSIP is 743187106. A total of 137 filers reported holding PROGENICS PHARMACEUTICALS IN in Q3 2019. The put-call ratio across all filers is 0.37 and the average weighting 0.0%.

Quarter-by-quarter ownership
PNC FINANCIAL SERVICES GROUP, INC. ownership history of PROGENICS PHARMACEUTICALS IN
ValueSharesWeighting
Q1 2020$16,000
-38.5%
4,277
-11.4%
0.00%
Q4 2019$26,000
+160.0%
4,830
+156.1%
0.00%
Q3 2019$10,000
-63.0%
1,886
-56.5%
0.00%
Q2 2019$27,000
+50.0%
4,338
+15.5%
0.00%
Q1 2019$18,000
+20.0%
3,757
+10.3%
0.00%
Q4 2018$15,0000.0%3,407
+45.6%
0.00%
Q3 2018$15,000
-21.1%
2,340
+1.1%
0.00%
Q2 2018$19,000
+46.2%
2,315
+24.7%
0.00%
Q1 2018$13,000
+18.2%
1,857
-0.3%
0.00%
Q4 2017$11,000
+266.7%
1,862
+375.0%
0.00%
Q3 2017$3,0000.0%392
-11.9%
0.00%
Q2 2017$3,0000.0%445
+45.9%
0.00%
Q1 2017$3,000
+50.0%
305
-45.7%
0.00%
Q2 2016$2,000
-33.3%
562
-3.6%
0.00%
Q1 2016$3,000
-89.3%
583
-87.2%
0.00%
Q4 2015$28,000
+7.7%
4,5630.0%0.00%
Q3 2015$26,000
-23.5%
4,563
+0.4%
0.00%
Q2 2015$34,000
+30.8%
4,544
+5.4%
0.00%
Q1 2015$26,000
-21.2%
4,311
-1.1%
0.00%
Q4 2014$33,000
+43.5%
4,361
-2.2%
0.00%
Q3 2014$23,000
+27.8%
4,4610.0%0.00%
Q2 2014$18,000
+5.9%
4,461
+7.5%
0.00%
Q1 2014$17,000
-29.2%
4,150
-2.4%
0.00%
Q4 2013$24,000
+9.1%
4,2500.0%0.00%
Q3 2013$22,000
+22.2%
4,250
+4.9%
0.00%
Q2 2013$18,0004,0500.00%
Other shareholders
PROGENICS PHARMACEUTICALS IN shareholders Q3 2019
NameSharesValueWeighting ↓
ARDSLEY ADVISORY PARTNERS LP 1,255,000$5,823,0001.12%
Phocas Financial Corp. 1,146,292$5,319,0000.54%
Worth Venture Partners, LLC 138,357$641,0000.36%
RICE HALL JAMES & ASSOCIATES, LLC 2,293,179$10,640,0000.34%
Monashee Investment Management LLC 240,000$1,114,0000.26%
BKS ADVISORS, LLC 118,587$550,0000.22%
PINNACLE ASSOCIATES LTD 1,418,391$6,581,0000.15%
FARALLON CAPITAL MANAGEMENT LLC 4,200,820$19,492,0000.15%
Fosun International Ltd 472,580$2,174,0000.14%
CARILLON TOWER ADVISERS, INC. 3,948,024$18,318,0000.13%
View complete list of PROGENICS PHARMACEUTICALS IN shareholders